Key facts
- This page summarizes George Poste's Form 4 filing for Caris Life Sciences, Inc. (CAI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 02 Jun 2026, 17:44.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
No transaction description listed
Additional SEC filing notes
Footnote F1
Shares issued in lieu of cash compensation for 2026 board retainer fees. Number of shares determined by dividing the cash retainer earned by the ten trading day average of the daily volume weighted average price per share through and including May 29, 2026.
Footnote F2
Amount reflects the previous transfer by the Reporting Person of 204,108 shares of Common Stock from direct ownership to a family trust. Following the transfer, these shares are held indirectly by the Reporting Person through the family trust and are reflected in the indirect ownership line. The transfer did not change the Reporting Person's aggregate beneficial ownership of these securities.